Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases

NCT07703683 | Recruiting DMC

• 1 other identifier: 2025/29OCT/445
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .

Conditions

Diabetes; Obesity & Overweight; Cushing Syndrome; Metabolic Diseases; Endocrine Diseases; Sarcopenia; Sarcopenic Obesity

Outcome Measures

Primary Outcomes (1)

• Prevalence of sarcopenia / sarcopenic obesity

  From February 2026 to december 2056

Secondary Outcomes (4)

• Myokines levels in serum or plasma

  February 2026 to December 2056

• Myokine expression

  February 2026 to December 2056

• Prevalence of MASLD

  March 2026 to December 2056

• Prevalence of MASH

  March 2026 to December 2056

Interventions

GLP-1 Receptor Agonists DRUG

Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity

Also known as: GLP-1/GIP dual agonists

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People with metabolic or endocrine diseases

You may qualify if:

• Metabolic or endocrine disease

You may not qualify if:

• Known myopathy
• Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
• Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
• History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor

Sponsors & Collaborators

• Cliniques universitaires Saint-Luc- Université Catholique de Louvain: lead

Study Sites (1)

Cliniques Universitaires Saint-Luc

Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, 1150, Belgium

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Serum, plasma, muscle tissue

MeSH Terms

Conditions

Diabetes Mellitus; Obesity; Overweight; Cushing Syndrome; Metabolic Diseases; Endocrine System Diseases; Sarcopenia

Interventions

Glucagon-Like Peptide-1 Receptor Agonists

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Nutritional and Metabolic Diseases; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical

Intervention Hierarchy (Ancestors)

Hypoglycemic Agents; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Central Study Contacts

Laura Orioli, MD, PhD

CONTACT

+32494507621; laura.orioli@saintluc.uclouvain.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2026
• First Posted: July 14, 2026
• Study Start: February 19, 2026
• Primary Completion (Estimated): December 31, 2056
• Study Completion (Estimated): December 31, 2056
• Last Updated: July 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)